Outlook Therapeutics announced the U.S. FDA has issued a CRL to the company’s BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoints, the Agency concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OTLK:
- Outlook Therapeutics (NASDAQ: OTLK) Craters 83% on FDA Setback
- Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
- Capital One says Outlook Therapeutics to receive ‘binary’ FDA decision today
- OTLK Earnings this Week: How Will it Perform?
- Outlook Therapeutics files to sell 516K shares of common stock for holders